Proteomic investigations into resistance in colorectal cancer

David Cantor, Harish Cheruku, Jack Westacott, Joo-Shik Shin, Abidali Mohamedali, Seong Beom Ahn

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Despite advances in screening and treatment options, colorectal cancer (CRC) remains one of the most prevalent and lethal cancer subtypes. Resistance to cytotoxic or targeted therapy has remained a constant challenge to the treatment and long-term management of patients, attracting intense worldwide investigation since the 1950s. Through extensive investigations into the proteomic mechanisms and functions that convey resistance to therapy/s, researchers have become able to implicate alterations in several signaling pathways that provide and sustain resistance to treatment.

Areas covered: In this review, we summarize how protein alterations are associated with resistance to therapy, with particular emphasis on CRC. An overview of the mechanisms of therapeutic resistance is described, highlighting recent studies which endeavor to elucidate the proteomic changes that are associated with the acquisition and promulgation of therapeutic resistance.

Expert opinion: While cancers such as CRC have been intensively studied for decades, unresponsiveness and the resistance to therapy remain critical obstacles in the treatment of patients. Due to the inherent biological and clinical heterogeneity of individual CRCs, proteomic methods stand to become powerful tools to provide biological insights that may guide therapeutic strategies with the ultimate goal of refining emergent immunotherapeutic treatments
Original languageEnglish
Pages (from-to)49-65
Number of pages17
JournalExpert Review of Proteomics
Volume17
Issue number1
Early online dateJan 2020
DOIs
Publication statusPublished - 2 Jan 2020

Keywords

  • Chemotherapy
  • colorectal cancer
  • cytotoxicity
  • proteomics
  • resistance

Fingerprint Dive into the research topics of 'Proteomic investigations into resistance in colorectal cancer'. Together they form a unique fingerprint.

  • Cite this